We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems' (VEEV) New Release to Address Supply-Chain Issues
Read MoreHide Full Article
Veeva Systems Inc. (VEEV - Free Report) recently announced a new cloud application, Veeva Vault Batch Release. The latest application will likely enable faster and more confident Good Manufacturing Processes release and market-ship decisions.
Vault Batch Release will be part of Veeva Vault Quality and is planned for availability in the second half of 2024.
The latest application is expected to provide a significant boost to the Veeva Vault Quality Suite under the Veeva Development Cloud solutions. Notably, the Veeva Development Cloud solutions belong to the broader Life Sciences segment and will likely automate data aggregation, reviews and traceability for greater efficiency and accuracy.
Significance of the Availability
Vault Batch Release is expected to address increased manufacturing and supply-chain complexity by streamlining the aggregation and review of data and content while simplifying collaboration with external partners.
Vault Batch Release will likely bring together data and content across QMS, LIMS, ERP and regulatory systems for real-time visibility into batch release status. The application will be integrated with and require Veeva Vault QMS. It is also expected to offer flexibility for use with other third-party LIMS and regulatory solutions.
Per management, Veeva Vault Batch Release will likely offer an automated, end-to-end solution for an underserved, complex process with compliance and cost risks. Management also believes that a digitalized and automated batch-release solution will likely aid in delivering products to Veeva Systems’ customers consistently, speedily and efficiently.
Industry Prospects
Per a report by Future Market Insights, the global electronic batch records market is expected to exceed $2627 million in 2023 and reach $8786.4 million by 2033 at a CAGR of 12.8%. Factors like cost reduction, easier tracking of the automated batch and the possibility of adverse impacts resulting from manual record keeping are expected to drive the market.
Given the market potential, the latest application is expected to strengthen Veeva Systems’ position in the niche space globally.
Notable Developments
Last month, Veeva Systems announced its second-quarter fiscal 2024 results, wherein it registered an uptick in the overall top and bottom lines and robust performances by both segments during the quarter. On the earnings call, management confirmed that broad-based adoption across Veeva Development Cloud was observed during the reported quarter, and the company advanced several major partnership opportunities with the top 20 pharmas.
The same month, Veeva Systems announced that Civica Rx adopted Veeva Vault LIMS to optimize quality control.
Price Performance
Shares of the company have gained 23.1% in the past year compared with the industry’s 19.9% rise and the S&P 500's 14.9% growth.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Veeva Systems carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , HealthEquity, Inc. (HQY - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 12.7%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita has gained 9% against the industry’s 8.4% decline over the past year.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 23.5%. HQY’s earnings surpassed estimates in all the trailing four quarters, with an average of 13%.
HealthEquity has lost 3.4% compared with the industry’s 12.6% decline over the past year.
Integer Holdings, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.
Integer Holdings has gained 30.3% against the industry’s 2.4% decline over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Veeva Systems' (VEEV) New Release to Address Supply-Chain Issues
Veeva Systems Inc. (VEEV - Free Report) recently announced a new cloud application, Veeva Vault Batch Release. The latest application will likely enable faster and more confident Good Manufacturing Processes release and market-ship decisions.
Vault Batch Release will be part of Veeva Vault Quality and is planned for availability in the second half of 2024.
The latest application is expected to provide a significant boost to the Veeva Vault Quality Suite under the Veeva Development Cloud solutions. Notably, the Veeva Development Cloud solutions belong to the broader Life Sciences segment and will likely automate data aggregation, reviews and traceability for greater efficiency and accuracy.
Significance of the Availability
Vault Batch Release is expected to address increased manufacturing and supply-chain complexity by streamlining the aggregation and review of data and content while simplifying collaboration with external partners.
Vault Batch Release will likely bring together data and content across QMS, LIMS, ERP and regulatory systems for real-time visibility into batch release status. The application will be integrated with and require Veeva Vault QMS. It is also expected to offer flexibility for use with other third-party LIMS and regulatory solutions.
Per management, Veeva Vault Batch Release will likely offer an automated, end-to-end solution for an underserved, complex process with compliance and cost risks. Management also believes that a digitalized and automated batch-release solution will likely aid in delivering products to Veeva Systems’ customers consistently, speedily and efficiently.
Industry Prospects
Per a report by Future Market Insights, the global electronic batch records market is expected to exceed $2627 million in 2023 and reach $8786.4 million by 2033 at a CAGR of 12.8%. Factors like cost reduction, easier tracking of the automated batch and the possibility of adverse impacts resulting from manual record keeping are expected to drive the market.
Given the market potential, the latest application is expected to strengthen Veeva Systems’ position in the niche space globally.
Notable Developments
Last month, Veeva Systems announced its second-quarter fiscal 2024 results, wherein it registered an uptick in the overall top and bottom lines and robust performances by both segments during the quarter. On the earnings call, management confirmed that broad-based adoption across Veeva Development Cloud was observed during the reported quarter, and the company advanced several major partnership opportunities with the top 20 pharmas.
The same month, Veeva Systems announced that Civica Rx adopted Veeva Vault LIMS to optimize quality control.
Price Performance
Shares of the company have gained 23.1% in the past year compared with the industry’s 19.9% rise and the S&P 500's 14.9% growth.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Veeva Systems carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , HealthEquity, Inc. (HQY - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 12.7%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita has gained 9% against the industry’s 8.4% decline over the past year.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 23.5%. HQY’s earnings surpassed estimates in all the trailing four quarters, with an average of 13%.
HealthEquity has lost 3.4% compared with the industry’s 12.6% decline over the past year.
Integer Holdings, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.
Integer Holdings has gained 30.3% against the industry’s 2.4% decline over the past year.